Synthetic Biologics, Inc.
3985 Research Park Drive, Suite 200
Ann Arbor
Michigan
48108
United States
Tel: 734-332-7800
Fax: 734-332-7878
Website: http://www.syntheticbiologics.com/
Email: info@syntheticbiologics.com
82 articles about Synthetic Biologics, Inc.
-
Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results
11/10/2020
-- Received Notice from the FDA that the SYN-004 (ribaxamase) Phase 1b/2a Clinical Program in Adult Allogeneic HCT Recipients May Proceed as Planned; Trial Commencement Anticipated in Q1 2021 -- -- Received Study-May-Proceed Letter from the FDA Supporting a Phase 1 Single Ascending Dose Study of SYN-020 IAP; Phase 1 Study to Support Development of SYN-020 in Multiple Indications -- Conference Call Today at 4:30 p.m. (ET) --
-
Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020
11/3/2020
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended September 30, 2020 on Tuesday, November 10, 2020,
-
Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients
10/2/2020
Synthetic Biologics, Inc., a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal diseases in areas of high unmet need, announced the results of a planned interim futility analysis of the investigator-sponsored Phase 2b clinical study of SYN-010 being conducted by Cedars-Sinai Medical Center.
-
Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results
8/6/2020
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the quarter ended June 30, 2020.
-
Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)
7/30/2020
Phase 1 Single Ascending Dose Study is Intended to Support the Clinical Development of SYN-020 in Multiple Indications
-
Synthetic Biologics to Report 2020 Second Quarter Operational Highlights and Financial Results on August 6, 2020
7/29/2020
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended June 30, 2020 on Thursday, August 6, 2020,
-
Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase
6/30/2020
Initial Indication Will Seek to Reduce Acute Intestinal Side Effects Associated with Radiation Therapy in Cancer Patients
-
Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases
5/27/2020
Synthetic Biologics, Inc. announced that it entered into an agreement with Massachusetts General Hospital granting the Company an option for an exclusive license to intellectual property and technology related to the use of intestinal alkaline phosphatase to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases.
-
Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results
5/5/2020
Company Updates Guidance and Clinical Development Timeline in Response to the COVID-19 Global Pandemic
-
Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020
4/28/2020
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended March 31, 2020
-
Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results
2/20/2020
-- Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 -- -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010 for the Treatment of IBS-C -- Conference Call Today at 4:30 p.m. (ET) --
-
Synthetic Biologics to Report 2019 Year End Operational Highlights and Financial Results on February 20, 2020
2/13/2020
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, intends to report operational highlights and financial results for the year ended December 31, 2019 on Thursday, February 20, 2020,
-
Synthetic Biologics to Present at the 2020 BIO CEO & Investor Conference
2/4/2020
Synthetic Biologics, Inc. (NYSE American: SYN), announced today that Steven A. Shallcross, Chief Executive and Financial Officer, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 10, 2020, at 11:00 a.m. (ET) at the New York Marriott Marquis (Wilder room).
-
Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients
1/7/2020
Synthetic Biologics, Inc. announced the receipt of official meeting minutes from the U.S. Food and Drug Administration following a Type C meeting held on December 2, 2019 at the Company's request to discuss the development of SYN-004 in allogeneic hematopoietic cell transplant recipients who are administered intravenous beta-lactam antibiotics in response to fever.
-
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
11/27/2019
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received written communication from NYSE American LLC (the "Exchange"), the Company's current listing exchange
-
Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results
11/4/2019
Synthetic Biologics, Inc. provided an operational update and reported financial results for the three and nine months ended September 30, 2019.
-
Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019
10/28/2019
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended September 30, 2019
-
Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
9/26/2019
Issuance of New Patent and Allowance of Patent Application Diversifies SYN-010 Protection in US
-
Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results
8/8/2019
Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic Hematopoietic Cell Transplant Recipients
-
Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019
8/1/2019
Conference Call Scheduled for Thursday, August 8, 2019 at 4:30 p.m. ET